Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. The EC50 for this effect is 1-3 ng/mL.
IL-28B/IFN-λ3 Protein, Human
IL-28B/IFN-λ3 Protein, Human
Price:
Regular price
$164.00 USD
Regular price
Sale price
$164.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Interferon lambda-3; IFN-lambda-3; Cytokine Zcyto22; Interleukin-28B (IL-28B); Interleukin-28C (IL-28C); |
| Accession | Q8IZI9 |
| Amino Acid Sequence | Val22-Val196 |
| Expression System | E.coli |
| Molecular Weight | 18 kDa (Reducing) |
| Purity | >95% by SDS-PAGE; >90% by HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801. |
Background
Interferon lambda 3 (IFN-λ3), also known as interleukin-28B (IL-28B), is a type III interferon that plays a crucial role in the innate immune response against viral infections. IFN-λ3 is produced in response to viral stimuli and exerts potent antiviral effects by inducing the expression of interferon-stimulated genes (ISGs) that inhibit viral replication and spread. Similar to other type III interferons, IFN-λ3 signals through the IFN-λ receptor complex, which consists of IL-10R2 and IL-28Rα subunits, leading to the activation of downstream signaling pathways involved in antiviral defense. IFN-λ3 has been implicated in the immune response to various viral infections, including hepatitis C virus (HCV) and influenza virus, and is considered a promising therapeutic target for the treatment of viral diseases.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
SEC-HPLC
>90% as determined by RP-HPLC.
